ALNY Earnings Date: Feb 11, 2027 (Estimated) — Alnylam Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ALNY's next earnings date?
Alnylam Pharmaceuticals, Inc. (ALNY) is expected to report Q4 2026 earnings on Thursday, February 11, 2027 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.56 on revenue of $1.57B.
How did ALNY do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Alnylam Pharmaceuticals, Inc. posted EPS of $16.26 versus the $1.66 estimate, a beat of 879.5%. Revenue was $1.46B against a $1.43B estimate. The stock's 1-day post-earnings move was -25.1%.
How much does ALNY stock move after earnings?
ALNY beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.8% (up or down) in the day after earnings.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
🤖 AI Earnings Analysis
Alnylam’s Q3 revenue rose 25% year over year to $1.5B, beating estimates, while reported EPS of $16.26 is distorted by an extraordinary comparison; the $5.3B–$5.7B revenue outlook supports a strong commercial trajectory.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 1.66 | 16.26 | +879.52% | $1.46B | ✅ Beat | -25.13% | — | — |
| 2026-07-30 | Q2 2026 | 2.00 | 1.84 | -8.00% | $1.29B | ❌ Miss | -28.31% | -20.20% | -17.47% |
| 2026-04-30 | Q1 2026 | 1.36 | 1.99 | +46.32% | $1.17B | ✅ Beat | +2.76% | +0.60% | +0.26% |
| 2026-02-12 | Q4 2025 | 1.20 | 1.25 | +4.17% | $1.10B | ✅ Beat | -4.28% | +5.30% | -2.75% |
| 2025-10-30 | Q3 2025 | 1.23 | 2.90 | +135.77% | $1.25B | ✅ Beat | -6.65% | -9.77% | -6.30% |
| 2025-07-31 | Q2 2025 | -0.16 | 0.32 | +300.00% | $773.7M | ✅ Beat | +15.43% | +26.00% | +33.12% |
| 2025-05-01 | Q1 2025 | -1.03 | -0.01 | +99.03% | $594.2M | ✅ Beat | -3.08% | +5.06% | +15.70% |
| 2025-02-13 | Q4 2024 | -0.14 | 0.06 | +142.86% | $593.2M | ✅ Beat | -0.40% | -5.62% | -9.10% |
Showing last 8 quarters.